<DOC>
	<DOCNO>NCT00960934</DOCNO>
	<brief_summary>The purpose study identify appropriate dose MK-5442 produce osteoanabolic effect without cause hypercalcemia postmenopausal woman osteoporosis .</brief_summary>
	<brief_title>A Dose-Ranging Study MK-5442 Postmenopausal Women With Osteoporosis ( MK-5442-001 )</brief_title>
	<detailed_description>Amendment 4 protocol change duration study 2 year 6 month .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Postmenopausal least 5 year No history fragility fracture , unless participant willing take market osteoporosis therapy candidate market osteoporosis therapy Agrees use medication osteoporosis except medication associate study Areal bone mineral density ( BMD ) Tscore &lt; 2.5 one follow 4 BMD site : total hip , femoral neck , trochanter , lumbar spine ≥ 3.5 4 BMD site . Participants unwilling take ineligible market osteoporosis therapy may one areal BMD Tscores &lt; 3.5 Unable undergo dualenergy Xray absorptiometry ( DXA ) scan due obesity ( ie , weight &gt; 250 lb ) Use oral bisphosphonates 6 month prior study screen , 3 month past 2 year , lifetime use 6 month Use intravenous bisphosphonates , strontium , growth hormone time Use phenytoin heparin within 2 week prior Visit 1 ; use raloxifene within 6 month prior Visit 1 Use pioglitazone rosiglitazone study screen Use estrogen ± progestin , form vaginal topical application , 6 month prior Study Visit 1 Prior total thyroidectomy Human immunodeficiency virus ( HIV ) positive acquire immune deficiency syndrome ( AIDS ) relate illness History malignant cancer within 5 year study screen , except certain skin cervical cancer History Paget 's disease and/or kidney stone An active user illicit drug History active alcohol abuse Participated investigational drug study within past 30 day</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>MK-5442</keyword>
</DOC>